Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

AT‐1RB use also showed an association with a lower risk of hospitalization due to any fracture (hazard ratio [HR] = 0.57, 95% confidence interval [CI] 0.40 to 0.81, p < 0.01) (Fig. 1A ) and hip fractures (HR = 0.37, 95% CI 0.19 to 0.73, p < 0.01) (Fig. 1B ), while the use of vitamin D receptor activators (VDRA) and phosphate binders did not show any association with hospitalization due to fractures.

Source: The association between AT‐1RB use and fractures in patients undergoing hemodialysis. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

The MBD‐5D study was a multicenter, prospective, observational study designed to follow patients with secondary hyperparathyroidism receiving maintenance hemodialysis for 3 years.

Source: Methods.

Forty percent (n = 3276) of patients were randomly selected as a subcohort, and their data were used in this analysis.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Type I Angiotensin II Receptor Blockade Reduces Uremia‐Induced Deterioration of Bone Material Properties

Observational study · Journal of Bone and Mineral Research · 2020

Original publication title

Type I Angiotensin II Receptor Blockade Reduces Uremia‐Induced Deterioration of Bone Material Properties

Takuya Wakamatsu; Yoshiko Iwasaki; Suguru Yamamoto; Koji Matsuo; Shin Goto; Ichiei Narita; Junichiro J Kazama; Kennichi Tanaka; Akemi Ito; Ryosuke Ozasa; Takayoshi Nakano; Chisato Miyakoshi; Yoshihiro Onishi; Shingo Fukuma; Shunichi Fukuhara; Hideyuki Yamato; Masafumi Fukagawa; Tadao Akizawa

© 2020 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR)

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

ABSTRACT

Chronic kidney disease (CKD) is associated with a high incidence of fractures. However, the pathophysiology of this disease is not fully understood, and limited therapeutic interventions are available. This study aimed to determine the impact of type 1 angiotensin II receptor blockade (AT‐1RB) on preventing CKD‐related fragility fractures and elucidate its pharmacological mechanisms. AT‐1RB use was associated with a lower risk of hospitalization due to fractures in 3276 patients undergoing maintenance hemodialysis. In nephrectomized rats, administration of olmesartan suppressed osteocyte apoptosis, skeletal pentosidine accumulation, and apatite disorientation, and partially inhibited the progression of the bone elastic mechanical properties, while the bone mass was unchanged.

Olmesartan suppressed angiotensin II‐dependent oxidation stress and apoptosis in primary cultured osteocytes in vitro. In conclusion, angiotensin II‐dependent intraskeletal oxidation stress deteriorated the bone elastic mechanical properties by promoting osteocyte apoptosis and pentosidine accumulation. Thus, AT‐1RB contributes to the underlying pathogenesis of abnormal bone quality in the setting of CKD, possibly by oxidative stress. © 2020 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Authors’ abstract

ABSTRACT

Chronic kidney disease (CKD) is associated with a high incidence of fractures. However, the pathophysiology of this disease is not fully understood, and limited therapeutic interventions are available. This study aimed to determine the impact of type 1 angiotensin II receptor blockade (AT‐1RB) on preventing CKD‐related fragility fractures and elucidate its pharmacological mechanisms. AT‐1RB use was associated with a lower risk of hospitalization due to fractures in 3276 patients undergoing maintenance hemodialysis. In nephrectomized rats, administration of olmesartan suppressed osteocyte apoptosis, skeletal pentosidine accumulation, and apatite disorientation, and partially inhibited the progression of the bone elastic mechanical properties, while the bone mass was unchanged.

Olmesartan suppressed angiotensin II‐dependent oxidation stress and apoptosis in primary cultured osteocytes in vitro. In conclusion, angiotensin II‐dependent intraskeletal oxidation stress deteriorated the bone elastic mechanical properties by promoting osteocyte apoptosis and pentosidine accumulation. Thus, AT‐1RB contributes to the underlying pathogenesis of abnormal bone quality in the setting of CKD, possibly by oxidative stress. © 2020 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

Publication and source details

Original title: Type I Angiotensin II Receptor Blockade Reduces Uremia‐Induced Deterioration of Bone Material Properties

Takuya Wakamatsu; Yoshiko Iwasaki; Suguru Yamamoto; Koji Matsuo; Shin Goto; Ichiei Narita; Junichiro J Kazama; Kennichi Tanaka; Akemi Ito; Ryosuke Ozasa; Takayoshi Nakano; Chisato Miyakoshi; Yoshihiro Onishi; Shingo Fukuma; Shunichi Fukuhara; Hideyuki Yamato; Masafumi Fukagawa; Tadao Akizawa

Journal of Bone and Mineral Research · 2020

* Address correspondence to: Junichiro J Kazama, MD, PhD, Department of Nephrology and Hypertension, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960 to 1295, Japan. E‐mail: jjkaz@fmu.co.jp
†

TW and YI contributed equally to this work.

© 2020 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR)https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T14:28:17.564454+00:00

DOI: 10.1002/jbmr.4159 · PMC9328427